Clinical trials: Alzheimer Dementia (AD)
Alzheimer Disease
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
The study is designed as a classic, randomized, double blind, placebo controlled, parallel group study including one active dose of PU AD and matching placebo, designed to assess safety, tolerability and pharmacological effects…
- Trial name
- NCT04311515
- Testing
- Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.
AD, Early Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment [MCI] due to AD, or…
- Trial name
- NCT07252440
- Testing
- TTYP01 tables 60mg, TTYP01 tables 90mg, TTYP01 tables 0mg
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Alzheimer Dementia (AD), Elderly
Therapy of Alzheimer's Disease With Neurofeedback
The project aims to investigate in patients of Alzheimer's disease in a prodromal state (early state of the disease) compared to healthy subjects whether neurofeedback training with functional MRI (fMRI) can improve cognitive…
- Trial name
- NCT03070821
- Testing
- rtfMRI neurofeedback training, 3T MRI
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aachen
Alzheimer's Disease (AD)
Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease
The aim of this clinical trial is to determine whether Lymphaticovenous Anastomosis can treat Alzheimer's disease，in AD patients aged 18-80.he main questions it aims to answer are: 1.
- Trial name
- NCT06706947
- Testing
- Lymphaticovenous Anastomosis
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Luo Xinxin
Alzheimer Dementia (AD), Mental Disorder
Efficacy of a Biodanza Program in People With Alzheimer's Disease.
This study aims to know the efficacy of a biodanza program in adults diagnosed with Alzheimer's, and it is a randomized controlled trial where the control group, which maintains its usual treatment, will form a waiting list to…
- Conditions
- Alzheimer Dementia (AD), Mental Disorder, Mood Disorders, Physically Disabled
- Trial name
- NCT04113967
- Testing
- Biodanza program
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Universidad de Almeria
Alzheimer Disease (AD)
Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease
This study aims to test a new artificial intelligence (AI) method to create brain scan images without needing an extra scan. Currently, patients with memory problems often undergo two types of PET scans (Amyloid PET and FDG PET)…
- Trial name
- NCT07431255
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- IRCCS San Raffaele
Alzheimer Disease, Healthy
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin.
- Trial name
- NCT04451408
- Testing
- LY3372993
- Where
- 13 sites in United States, Japan
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Dementia, Dementia
Low-Dose Radiotherapy for Alzheimer's Disease
To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10…
- Conditions
- Alzheimer Dementia, Dementia, Alzheimer Dementia (AD), Alzheimer
- Trial name
- LDRT-MIND (NCT07693140)
- Testing
- Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Evan Thomas
Alzheimer Disease
Open-Label Extension Protocol to SNK01-AD01 Study
Open-Label Extension Protocol to SNK01-AD01 Study
- Trial name
- NCT07228078
- Testing
- SNK01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NKGen Biotech, Inc.
Alzheimer Disease (AD), Cardio Vascular Disease
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
The Arlington Longitudinal Optimal Healthy Aging (ALOHA) Study is a community-based research project led by the Marymount University Center for Optimal Aging (MCOA).
- Conditions
- Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome
- Trial name
- ALOHA (NCT07180147)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Marymount University
Alzheimer's Disease
Computer-Based Training for Mild Alzheimer's Disease
The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).
- Trial name
- NCT00319891
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Posit Science Corporation
Lymphoma, Solid Malignancy
PET Imaging of Subjects Using 124I-PU-AD
This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Trial name
- NCT03371420
- Testing
- PU-AD, PET Scan, Blood Draws
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Samus Therapeutics, Inc.
Wisconsin Alzheimer's Disease Research Center, Wisconsin Registry for Alzheimer's Prevention
Speech Pattern Evaluation and Analysis for Knowledge of AD
The goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias (ADRD).
- Trial name
- SPEAK-AD (NCT06230783)
- Testing
- TalkTracker
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Suspected Typical Alzheimer's Disease (AD), Suspected Atypical Alzheimer's Disease (AD)
VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)
The overarching goal of this study is to a) assess the feasibility and preliminary validity of home-based delivery of TeleNP to patients with suspected Alzheimer's Disease (AD), referred for cognitive assessments in a Neurology…
- Trial name
- VITAL-NP (NCT05379023)
- Testing
- Face-to-face evaluation (FF), TeleNP evaluation
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Colorado, Denver
Alzheimer's Disease
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older.
- Trial name
- NCT01466088
- Testing
- Donepezil, AZD3480
- Where
- 33 sites in United States, Czechia and 3 more
- Volunteers
- 386 people
- Sponsor
- Targacept Inc.
Alzheimer Disease
I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD
The imdazoline2 binding site (I2BS) is known to reside inside astrocytes. Changes in the numbers of I2BS in post mortem tissue has implicated them in a range of psychiatric conditions such as depression and addiction, along with…
- Trial name
- I2PETPG (NCT02874820)
- Testing
- [11C]BU99008, Idazoxan
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Imperial College London
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
This multicenter study aims to characterize the language profiles of patients with various neurodegenerative diseases, including Alzheimer's disease (AD), Primary Progressive Aphasia (PPA), behavioral variant Frontotemporal…
- Conditions
- Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Parkinsons Disease (PD), Lewy Body Dementia
- Trial name
- AILAN (NCT07906769)
- Testing
- Speech and language Test to support clinical diagnosis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Early Alzheimer's Disease
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
- Trial name
- APOLLOE4-LTE (NCT06304883)
- Testing
- Experimental: ALZ-801
- Where
- 41 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Alzheon Inc.
Alzheimer Disease, Dementia
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease
The goal of this double-blinded placebo-controlled randomized trial is to determine the optimal dose of nicotinamide riboside (NR), in individuals with Alzheimer's disease (AD).
- Trial name
- NCT05617508
- Testing
- Nicotinamide Riboside supplementation 1000mg daily in total, Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)
- Where
- 2 sites in Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Alzheimer's Disease
Online Caregiver Psychoeducation and Support for Alzheimer's
This study is piloting an internet-based intervention to provide support for caregivers of VA patients with Alzheimer's disease or related memory difficulties (ADRD).
- Trial name
- NCT00416078
- Testing
- caregiver website support, caregiver brief supportive phone calls
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- US Department of Veterans Affairs